Patents by Inventor Wolfgang Schäfer

Wolfgang Schäfer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240141044
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: July 6, 2023
    Publication date: May 2, 2024
    Inventors: Oliver AST, Marina BACAC, Sabine IMHOF-JUNG, Christiane NEUMANN, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
  • Patent number: 11952421
    Abstract: The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: April 9, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Tanja Fauti, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Ramona Murr, Pablo Umana, Sabine Jung-Imhof, Stefan Klostermann, Michael Molhoj, Joerg Regula, Wolfgang Schaefer
  • Publication number: 20230399391
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: January 5, 2023
    Publication date: December 14, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine lmhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • Publication number: 20230365702
    Abstract: Herein are provided bispecific anti-human A-beta/human transferrin receptor antibodies and methods of using the same.
    Type: Application
    Filed: April 10, 2023
    Publication date: November 16, 2023
    Inventors: Harald Duerr, Sebastian Fenn, Ulrich Goepfert, Sabine Imhof-Jung, Christian Klein, Laurent Lariviere, Michael Molhoj, Joerg Thomas Regula, Petra Rueger, Wolfgang Schaefer
  • Patent number: 11787868
    Abstract: Herein are provided bispecific anti-human A-betalhuman transferrin receptor antibodies and methods of using the same.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: October 17, 2023
    Inventors: Harald Duerr, Sebastian Fenn, Ulrich Goepfert, Sabine Imhof-Jung, Christian Klein, Laurent Lariviere, Michael Molhoj, Joerg Thomas Regula, Petra Rueger, Wolfgang Schaefer
  • Patent number: 11787873
    Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: October 17, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Rebecca Croasdale-Wood, Lydia Jasmin Hanisch, Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Claudio Sustmann, Pablo Umana
  • Publication number: 20230287118
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: October 13, 2022
    Publication date: September 14, 2023
    Inventors: Oliver AST, Marina Bacac, Sabine Imhof-Jung, Christiane Neumann, Christian Klein, Stefan Klostermann, Michael Molhoj, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
  • Patent number: 11680110
    Abstract: Herein is reported a method for the humanization of non-human antibodies using a structure-based scoring matrix. With the scoring matrix it is possible to determine (the requirement for and) the suitability of specific (back)mutations of amino acid residues at defined positions of a selected human germline sequence. The scoring matrix takes into account the topology, the three-dimensional structure and the interactions of the respective residue and change. Thereby the influence on antigen binding of a specific amino acid residue change can be determined.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: June 20, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Johannes Auer, Guy Georges, Stefan Klostermann, Wolfgang Schaefer
  • Patent number: 11673945
    Abstract: The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: June 13, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Sabine Imhof-Jung, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer
  • Patent number: 11618790
    Abstract: Herein is reported a polypeptide-polynucleotide-complex as therapeutic agent and its use as tool for the targeted delivery of an effector moiety. The polynucleotide part of the complex is essentially resistant to proteolytic and enzymatic degradation in vivo. Additionally the polypeptide part specifically binds to a compound or structure such as a tissue or organ, a process or a disease. Thus, one aspect as reported herein is a polypeptide-polynucleotide-complex comprising a) a polypeptide specifically binding to a target and conjugated to a first member of a binding pair, b) a polynucleotide linker conjugated at its first terminus to the second member of the binding pair, and c) an effector moiety conjugated to a polynucleotide that is complementary to at least a part of the polynucleotide linker.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: April 4, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Michael Gerg, Dieter Heindl, Gerhard Niederfellner, Wolfgang Schaefer, Michael Schraeml, Michael Tacke
  • Patent number: 11603411
    Abstract: Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: March 14, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Harald Duerr, Sebastian Fenn, Ulrich Goepfert, Sabine Imhof-Jung, Christian Klein, Laurent Lariviere, Michael Molhoj, Joerg Thomas Regula, Petra Rueger, Wolfgang Schaefer
  • Publication number: 20230068801
    Abstract: The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.
    Type: Application
    Filed: April 28, 2022
    Publication date: March 2, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Sabine IMHOF-JUNG, Christian KLEIN, Stefan KLOSTERMANN, Joerg Thomas REGULA, Wolfgang SCHAEFER
  • Publication number: 20220403027
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: April 1, 2022
    Publication date: December 22, 2022
    Inventors: Oliver AST, Marina BACAC, Sabine IMHOF-JUNG, Christiane NEUMANN, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
  • Publication number: 20220363771
    Abstract: The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.
    Type: Application
    Filed: January 27, 2022
    Publication date: November 17, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg Thomas REGULA, Wolfgang SCHAEFER, Michael MOLHOJ, Sabine IMHOF-JUNG, Christian KLEIN
  • Publication number: 20220324955
    Abstract: Herein is reported an IgG class Fc-region comprising a first variant Fc-region polypeptide and a second variant Fc-region polypeptide, wherein the first variant Fc-region polypeptide is derived from a first parent IgG class Fc-region polypeptide and the second variant Fc-region polypeptide is derived from a second parent IgG class Fc-region polypeptide, whereby the first parent IgG class Fc-region polypeptide is identical to or different from the second parent IgG class Fc-region polypeptide, and the first variant Fc-region polypeptide differs from the second variant Fc-region polypeptide in one or more amino acid residues other than those amino acid residues in which the first parent IgG class Fc-region polypeptide differs from the second parent IgG class Fc-region polypeptide, and the IgG class Fc-region comprising the first variant Fc-region polypeptide and the second variant Fc-region polypeptide has an affinity to a human Fc-receptor that is different than that of an IgG class Fc-region comprising the fi
    Type: Application
    Filed: May 26, 2022
    Publication date: October 13, 2022
    Inventors: Joerg Thomas Regula, Wolfgang Schaefer, Tilman Schlothauer
  • Publication number: 20220306761
    Abstract: Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 29, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Harald DUERR, Sebastian FENN, Ulrich GOEPFERT, Sabine IMHOF-JUNG, Christian KLEIN, Laurent LARIVIERE, Michael MOLHOJ, Joerg Thomas REGULA, Petra RUEGER, Wolfgang SCHAEFER
  • Publication number: 20220144963
    Abstract: Herein are provided bispecific anti-human A-betalhuman transferrin receptor antibodies and methods of using the same.
    Type: Application
    Filed: December 22, 2020
    Publication date: May 12, 2022
    Inventors: Harald Duerr, Sebastian Fenn, Ulrich Goepfert, Sabine Imhof-Jung, Christian Klein, Laurent Lariviere, Michael Molhoj, Joerg Thomas Regula, Petra Rueger, Wolfgang Schaefer
  • Publication number: 20220049020
    Abstract: The present invention relates to novel tetravalent multispecific antibodies, their manufacture and use.
    Type: Application
    Filed: April 6, 2021
    Publication date: February 17, 2022
    Inventors: Joerg Thomas REGULA, Stefan SEEBER, Wolfgang SCHAEFER, Sabine IMHOF-JUNG, Michael MOLHOJ, Maximiliane KOENIG, Peter BRUENKER, Christian KLEIN
  • Publication number: 20210395355
    Abstract: Herein is reported the use of an antibody comprising an Fc-region with abolished FcRn binding for the transport of a soluble receptor ligand from the eye over the blood-ocular-barrier into the blood circulation.
    Type: Application
    Filed: July 12, 2021
    Publication date: December 23, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guido Hartmann, Joerg Regula, Matthias Rueth, Wolfgang Schaefer, Tilman Schlothauer
  • Publication number: 20210309730
    Abstract: The present invention relates to multispecific antibodies, their manufacture and use.
    Type: Application
    Filed: November 25, 2020
    Publication date: October 7, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Wolfgang SCHAEFER, Christian KLEIN, Sabine IMHOF-JUNG, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg Thomas REGULA